AdhereTech appoints Paul Sekhri to board of directors

AdhereTech has announced that it has appointed Paul Sekhri to its board of directors, having begun his new role on 7 February 2024.
Paul brings with him over 30 years of experience in the life sciences industry, including various senior leadership roles at large pharmaceutical and biotechnology companies, as well as private equity and venture capital firms. Currently, Paul is working as president and chief executive officer (CEO) of vTv Therapeutics.
Prior to this, Paul has worked as president and CEO of eGenesis and Lycera Corp, as well as other senior roles at Sanofi, Teva Pharmaceutical Industries, TOG Biotech, Cerimon Pharmaceuticals and Novartis.
Neale Trangucci, chair of the board, commented: “We are excited to have Paul join the AdhereTech board of directors. His many years of experience in both biotech and pharma companies, as well as on the investment side, and his exceptional industry network will be invaluable to AdhereTech as the company continues to expand its growing client base of leading pharma clients. I look forward to working closely with Paul and to utilising his expertise to support the management team as it drives the company forward.”
Commenting on his latest appointment, Paul said: “I welcomed the opportunity to join the Board of AdhereTech as I see that the company’s Aidia real-time adherence technology can effectively address a major issue – non-adherence to medication. This problem is costly to a patient’s health and to the healthcare system overall. I look forward to working with my fellow Board members and the management team to help ensure AdhereTech’s solutions get to those who need them.”